Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
Trial record 1 of 6 for:    e2810
Previous Study | Return to List | Next Study

Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery

This study is currently recruiting participants. (see Contacts and Locations)
Verified November 2014 by National Cancer Institute (NCI)
Sponsor:
Information provided by (Responsible Party):
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT01575548
First received: April 10, 2012
Last updated: November 24, 2014
Last verified: November 2014

April 10, 2012
November 24, 2014
August 2012
August 2022   (final data collection date for primary outcome measure)
Disease-free survival (DFS) [ Time Frame: Time from randomization to recurrence, development of second primary cancer, or death from any cause, assessed up to 10 years ] [ Designated as safety issue: No ]
Spearman's Rank Correlation Coefficient will be calculated to test whether there is a relationship between pazopanib hydrochloride trough levels and DFS.
Disease-free survival at 3 years [ Designated as safety issue: No ]
Complete list of historical versions of study NCT01575548 on ClinicalTrials.gov Archive Site
  • Overall survival [ Time Frame: Time from randomization to date of death, assessed up to 10 years ] [ Designated as safety issue: No ]
    Overall survival for each treatment group will be partitioned into three health states: toxicity, time without symptoms of disease or toxicity, and recurrence.
  • Toxicity, defined as time spent with grade 3 or 4 adverse events prior to disease recurrence as assessed by the National Cancer Institute CTCAE version 4.0 [ Time Frame: Up to 10 years ] [ Designated as safety issue: Yes ]
    The number of days between randomization and disease recurrence with any adverse event of grade 3 or 4 will be counted.
  • Change in Q-TWiST between the two arms as assessed by the European Quality of Life 5-Dimensions [ Time Frame: From baseline to up to 10 years ] [ Designated as safety issue: No ]
    The mean amount of time in each state will be estimated using the method of Kaplan and Meier (1958).
  • Change in fatigue as assessed by Patient Reported Outcome Measurement Information System Fatigue and Functional Assessment of Chronic Illness Therapy Fatigue subscales [ Time Frame: From baseline to 15 months ] [ Designated as safety issue: No ]
  • Change in kidney cancer-related symptoms as assessed by the Functional Assessment of Cancer Therapy-Kidney Cancer Symptom Index [ Time Frame: From baseline to 15 months ] [ Designated as safety issue: No ]
  • Plasma trough levels of pazopanib hydrochloride [ Time Frame: Day 1 of course 2 ] [ Designated as safety issue: No ]
    The association of plasma trough levels of pazopanib hydrochloride with disease-free and overall survival will be explored.
  • Prospective banking of preserved tissue from primary tumors and associated metastatic sites [ Time Frame: Baseline ] [ Designated as safety issue: No ]
  • Overall survival at 1 year [ Designated as safety issue: No ]
  • Treatment and disease-related toxicity as assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 [ Designated as safety issue: Yes ]
  • Q-TWiST between the two arms as assessed by EQ-5D [ Designated as safety issue: No ]
  • Fatigue as assessed by PROMIS--Fatigue scale [ Designated as safety issue: No ]
  • Kidney cancer-related symptoms as assessed by FKSI-15 [ Designated as safety issue: No ]
Not Provided
Not Provided
 
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery
Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastasectomy

This randomized phase III trial studies how well pazopanib hydrochloride works compared to placebo in treating patients with metastatic kidney cancer who have no evidence of disease after surgery. Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.

PRIMARY OBJECTIVES:

I. To evaluate disease-free survival with pazopanib (pazopanib hydrochloride) as compared to placebo, defined as the time from randomization to the development of recurrent disease, second primary cancer (other than localized breast, localized prostate, or non-melanoma skin cancer) or death from any cause for patients with metastatic renal cell carcinoma (RCC) with no evidence of disease following metastasectomy.

SECONDARY OBJECTIVES:

I. To describe the overall survival of patients with advanced RCC randomly assigned to receive placebo or pazopanib for one year following metastasectomy to no evidence of disease (NED).

II. To describe treatment and (at recurrence) disease-related adverse events in the two treatment arms.

III. To analyze quality-adjusted time without symptoms of disease or treatment (Q-TWiST) for subjects in the two treatment arms.

IV. To characterize changes in patient-reported fatigue and (at recurrence) kidney cancer-related symptoms during and following treatment with pazopanib compared to placebo.

V. To explore the association between plasma trough levels of pazopanib and disease-free and overall survival.

VI. To prospectively bank preserved tissue from primary tumors and associated metastatic sites in patients with RCC.

OUTLINE: Patients are randomized to 1of 2 treatment arms.

ARM I: Patients receive pazopanib hydrochloride orally (PO) once daily (QD) on days 1-28. Treatment repeats every 28 days for up to 13 courses in the absence of disease progression or unacceptable toxicity.

ARM II: Patients receive placebo PO QD on days 1-28. Treatment repeats every 28 days for up to 13 courses in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up every 3 months for the first two years, every 6 months for the next 3 years, and then annually up to 10 years.

Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
  • Clear Cell Renal Cell Carcinoma
  • Recurrent Renal Cell Carcinoma
  • Stage IV Renal Cell Cancer
  • Drug: Pazopanib Hydrochloride
    Given PO
    Other Names:
    • GW786034B
    • Votrient
  • Other: Placebo
    Given PO
    Other Name: PLCB
  • Other: Quality-of-Life Assessment
    Ancillary studies
    Other Name: Quality of Life Assessment
  • Other: Questionnaire Administration
    Ancillary studies
  • Other: Pharmacological Study
    Correlative studies
    Other Name: pharmacological studies
  • Experimental: Arm I (pazopanib hydrochloride)
    Patients receive pazopanib hydrochloride PO QD on days 1-28. Treatment repeats every 28 days for up to 13 courses in the absence of disease progression or unacceptable toxicity.
    Interventions:
    • Drug: Pazopanib Hydrochloride
    • Other: Quality-of-Life Assessment
    • Other: Questionnaire Administration
    • Other: Pharmacological Study
  • Placebo Comparator: Arm II (placebo)
    Patients receive placebo PO QD on days 1-28. Treatment repeats every 28 days for up to 13 courses in the absence of disease progression or unacceptable toxicity.
    Interventions:
    • Other: Placebo
    • Other: Quality-of-Life Assessment
    • Other: Questionnaire Administration
    • Other: Pharmacological Study
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
128
Not Provided
August 2022   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patient must have pathologically confirmed renal cell carcinoma with a clear cell component; pure papillary and chromophobe histologies are excluded; there must be pathologic confirmation of metastatic disease in the resected metastasectomy specimen
  • Patient must have undergone nephrectomy or partial nephrectomy to remove primary renal cell carcinoma (at any time in the past)
  • Patient must have undergone surgical resection to remove one or more sites of metastatic disease, with successful removal of all known sites 2-12 weeks prior to randomization; any number of prior metastasectomies may have been performed in the past, so long as the most recent procedure was within the 12 weeks of registration; the most recent procedure may be nephrectomy for a renal primary tumor
  • Patients with synchronous disease at initial diagnosis must have metastatic (M1) disease (American Joint Committee on Cancer [AJCC] 7th edition T1-4N0-1M1)
  • Positive surgical margins are permitted if the surgeon confirms complete resection of gross metastatic disease, and post-operative scans are negative
  • Patients presenting with metachronous disease may have distant metastases, regional lymph node or renal bed recurrence; recurrences at a partial nephrectomy resection site are not eligible if it is the only site of disease
  • Patients presenting with tumors within the kidneys (multiple synchronous or single/multiple metachronous) are not eligible if there are no extrarenal sites of disease (i.e. potential multifocal primary disease)
  • Patient must have no evidence of disease on post-operative imaging:

    • A computed tomography (CT) of the chest must be obtained within 4 weeks prior to randomization with or without contrast
    • A CT of the abdomen/pelvis must be obtained within 4 weeks prior to randomization with intravenous (IV) contrast (oral contrast may be added at the radiologist's discretion); an MRI of the abdomen/pelvis with gadolinium may be substituted for the CT if the CT with IV contrast is contra-indicated
    • An MRI of the brain with and without gadolinium must be done within 8 weeks prior to randomization; a CT of the brain with and without IV contrast is permitted if MRI is contra-indicated (i.e., pacemaker)
  • Patient must not have received any prior or concurrent systemic therapy for RCC; adjuvant placebo administration is permitted
  • Patient must have no active peptic ulcer disease
  • Patient must have no active inflammatory bowel disease
  • Patient must have no New York Heart Association (NYHA) class II or greater congestive heart failure
  • Patient must have no prior history or current clinically apparent central nervous system metastases
  • Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 at the time of randomization
  • Absolute granulocyte count > 1,500/mcL
  • Platelets > 100,000/mcL
  • Total bilirubin < 1.5 x institutional upper limit of normal (ULN)
  • Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) < 2.5 x upper limit of normal (ULN)
  • Calculated creatinine clearance (CrCl) > 30 mL/min
  • Subjects must have a urine protein/creatinine (UPC) ratio < 1; if UPC >= 1, then a 24-hour urine total protein must be obtained; subjects must have a 24-hour urine protein value < 1 g to be eligible; use of urine dipstick for renal function assessment is not acceptable
  • Women must not be pregnant or breast-feeding

    • All females of childbearing potential must have a blood test or urine study within 2 weeks prior to randomization to rule out pregnancy; a female of childbearing potential is any woman, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months)
  • Women of childbearing potential and sexually active males must be strongly advised to use an accepted and effective method of contraception or to abstain from sexual intercourse for the duration of their participation in the study; should a woman become pregnant while participating in this study, she should inform her treating physician immediately; if a man impregnates a woman while participating in this study, he should inform his treating physician immediately
  • Patient must be able to swallow pills and have no significant impairment in gastrointestinal absorption including history of gastric bypass surgery
  • Patient must have no history of allergic reactions attributed to compounds of similar chemical or biologic composition to pazopanib
  • Patient must have no uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
  • Patient must have a corrected QT (QTc) interval on electrocardiogram (ECG) =< 0.48 seconds by Bazett's calculation (=< Common Terminology Criteria for Adverse Events [CTCAE] version [v.]4 grade 2) prior to randomization
  • Patient must have a systolic blood pressure =< 140 mmHg and diastolic blood pressure must be =< 90 mmHg, measured within 4 weeks prior to randomization; initiation or adjustment of anti-hypertensives prior to starting study treatment is allowed
  • Patient must not have serious or non-healing wound, ulcer, or bone fracture at the time of randomization
  • Patient must have no history of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 4 weeks prior to randomization
  • Patient must have no history of cerebrovascular accident (CVA) within 6 months of randomization
  • Patient must have no history of myocardial infarction, hospital admission for unstable angina, cardiac angioplasty or stenting within 6 months of randomization
  • Patient must have no history of venous thrombosis within 12 weeks of randomization
  • Patient cannot be taking strong cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4) inhibitors such as:

    • Antibiotics: clarithromycin, telithromycin, troleandomycin
    • Human immunodeficiency virus (HIV) antiviral protease inhibitors: ritonavir, indinavir, saquinavir, nelfinavir, amprenavir, lopinavir
    • Antifungals: itraconazole, ketoconazole, voriconazole, fluconazole
    • Antidepressants: nefazodone
  • Patient must not have history of hemoptysis in excess of 2.5 mL (1/2 teaspoon) within 8 weeks prior to randomization
  • Patient must not be taking drugs known to prolong the QTc interval; such drugs should be discontinued at least 5 half-lives prior to randomization
  • Patients must not have any history of other cancer within 3 years from time of randomization with the exception of basal cell skin cancer, squamous cell skin cancer, in situ cervical cancer, ductal or lobular carcinoma in situ of the breast, or resected non-invasive (Ta) urothelial carcinoma
Both
18 Years and older
No
United States
 
NCT01575548
NCI-2012-00723, NCI-2012-00723, CDR0000730383, ECOG-E2810, E2810, E2810, U10CA180820, U10CA021115
Yes
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Not Provided
Principal Investigator: Leonard Appleman ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)
November 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP